Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China

Clinical trial NCT07161388 · RECRUITING

Trial details

NCT number: NCT07161388
Sponsor: AstraZeneca
Status: RECRUITING
Study type: OBSERVATIONAL

Limited Stage Small-Cell Lung Cancer

Start date: 2025-11-17
Primary completion: 2028-09-30
Enrollment: 200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.